Cumberland Pharmaceuticals (CPIX) Reports Q4 EPS of $0.10
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Cumberland Pharma (CPIX) Announces Achieving Several Clinical, Regulatory Milestones; Provides Update
March 4, 2015 6:39 AM ESTCumberland Pharmaceuticals (NASDAQ: CPIX) announced achievement of several clinical and regulatory milestones. These developments include top-line results from the Company's Hepatoren Phase II study, submission of a supplemental New Drug Application (sNDA) with pediatric data for Caldolor and initiation of patient enrollment in the Boxaban Phase II clinical trial.
"The sNDA for Caldolor represents a key milestone following the conclusion of a series of important Phase IV studies for the product. We look forward to working with the FDA with the goal of adding pediatric information to the Caldolor label," said A.J. Kazimi,... More
